Details of the Drug | DrugMAP

General Information of Drug (ID: DMMNIU4)

Drug Name

Betalutin

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1	[2]

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C30H47N7O10S
Canonical SMILES: C1CN(CCN(C(CN(CCN1CC(=O)O)CC(=O)O)CC2=CC=C(C=C2)NC(=S)NCCCCC(C(=O)O)N)CC(=O)O)CC(=O)O
InChI: InChI=1S/C30H47N7O10S/c31-24(29(46)47)3-1-2-8-32-30(48)33-22-6-4-21(5-7-22)15-23-16-36(19-27(42)43)12-11-34(17-25(38)39)9-10-35(18-26(40)41)13-14-37(23)20-28(44)45/h4-7,23-24H,1-3,8-20,31H2,(H,38,39)(H,40,41)(H,42,43)(H,44,45)(H,46,47)(H2,32,33,48)/t23?,24-/m0/s1
InChIKey: RMJFCRKHOJOLIN-CGAIIQECSA-N

Cross-matching ID

PubChem CID: 131704322
TTD ID: D0B9XW

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT01796171) A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)